Retinal oximetry: Metabolic imaging for diseases of the retina and brain.

Alzheimer's disease Biomarker Brain Cardiac output Central circulation Classification Diabetic retinopathy Eye Glaucoma Heart Multiple sclerosis Oxygen Progression of glaucoma Retina Retinal atrophy Retinal dystrophy Retinal oximetry Retinal vein occlusion, retinal ischemia Retinitis pigmentosa

Journal

Progress in retinal and eye research
ISSN: 1873-1635
Titre abrégé: Prog Retin Eye Res
Pays: England
ID NLM: 9431859

Informations de publication

Date de publication:
05 2019
Historique:
received: 21 12 2018
revised: 27 03 2019
accepted: 10 04 2019
pubmed: 19 4 2019
medline: 8 2 2020
entrez: 19 4 2019
Statut: ppublish

Résumé

Retinal oximetry imaging of retinal blood vessels measures oxygen saturation of hemoglobin. The imaging technology is non-invasive and reproducible with remarkably low variability on test-retest studies and in healthy cohorts. Pathophysiological principles and novel biomarkers in several retinal diseases have been discovered, as well as possible applications for systemic and brain disease. In diabetic retinopathy, retinal venous oxygen saturation is elevated and arteriovenous difference progressively reduced in advanced stages of retinopathy compared with healthy persons. This correlates with pathophysiology of diabetic retinopathy where hypoxia stimulates VEGF production. Laser treatment and vitrectomy both improve retinal oximetry values, which correlate with clinical outcome. The oximetry biomarker may allow automatic measurement of severity of diabetic retinopathy and predict its response to treatment. Central retinal vein occlusion is characterized by retinal hypoxia, which is evident in retinal oximetry. The retinal hypoxia seen on oximetry correlates with the extent of peripheral ischemia, visual acuity and thickness of macular edema. This biomarker may help diagnose and measure severity of vein occlusion and degree of retinal ischemia. Glaucomatous retinal atrophy is associated with reduced oxygen consumption resulting in reduced arteriovenous difference and higher retinal venous saturation. The oximetry findings correlate with worse visual field, thinner nerve fiber layer and smaller optic disc rim. This provides an objective biomarker for glaucomatous damage. In retinitis pigmentosa, an association exists between advanced atrophy, worse visual field and higher retinal venous oxygen saturation, lower arteriovenous difference. This biomarker may allow measurement of severity and progression of retinitis pigmentosa and other atrophic retinal diseases. Retinal oximetry offers visible light imaging of systemic and central nervous system vessels. It senses hypoxia in cardiac and pulmonary diseases. Oximetry biomarkers have been discovered in Alzheimer's disease and multiple sclerosis and oxygen levels in the retina correspond well with brain.

Identifiants

pubmed: 30999027
pii: S1350-9462(18)30080-6
doi: 10.1016/j.preteyeres.2019.04.001
pii:
doi:

Substances chimiques

Oxygen S88TT14065

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-22

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Einar Stefánsson (E)

University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland; Oxymap ehf, Reykjavik, Iceland. Electronic address: einarste@landspitali.is.

Olof Birna Olafsdottir (OB)

University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland.

Thorunn S Eliasdottir (TS)

University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland.

Wouter Vehmeijer (W)

Leiden University, Leiden, the Netherlands.

Anna Bryndis Einarsdottir (AB)

University of Iceland, Reykjavik, Iceland; Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.

Toke Bek (T)

Aarhus University Hospital, Aarhus, Denmark.

Thomas Lee Torp (TL)

Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.

Jakob Grauslund (J)

Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark.

Thor Eysteinsson (T)

University of Iceland, Reykjavik, Iceland; Landspitali, University Hospital, Reykjavik, Iceland.

Robert Arnar Karlsson (RA)

University of Iceland, Reykjavik, Iceland; Oxymap ehf, Reykjavik, Iceland.

Karel Van Keer (K)

University of Leuven, Leuven, Belgium.

Ingeborg Stalmans (I)

University of Leuven, Leuven, Belgium.

Evelien Vandewalle (E)

University of Leuven, Leuven, Belgium.

Margarita G Todorova (MG)

University of Basel, Department of Ophthalmology, Basel, Switzerland; Cantonal Hospital St.Gallen, Department of Ophthalmology, St. Gallen, Switzerland.

Martin Hammer (M)

Universitätsklinikum Jena, Germany.

Gerhard Garhöfer (G)

Department of Clinical Pharmacology, Medical University of Vienna, Austria.

Leopold Schmetterer (L)

Singapore Eye Research Institute, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Ophthalmology and Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore; Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Austria.

Martin Šín (M)

Department of Ophthalmology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.

Sveinn Hakon Hardarson (SH)

University of Iceland, Reykjavik, Iceland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH